Butryate Supplementation May Support Pediatric Obesity Treatment
December 07, 2022

Findings from a new study suggest that supplementing standard care for obesity with butyrate helped reduce BMI, improve glucose metabolism, and reduce inflammation markers.

Diabetes and Obesity: Why Obesity Treatment Should Come First
December 02, 2022

An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.

Doubling Levonorgestrel Dose Fails to Prevent Pregnancy in Women with Obesity
November 27, 2022

The "Plan B" emergency contraceptive at 2 times the normal dose was not more effective in study participants with BMI >30.

FDA Approves Teplizumab, First Drug Indicated to Prevent Type 1 Diabetes
November 18, 2022

Teplizumab, an anti-CD3 monoclonal antibody, delayed the median onset of stage 3 T1D by approximately 2 years compared to placebo in a pivotal clinical trial.

The Promise of Precision Medicine for Obesity: It Should be Simple
November 18, 2022

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
November 15, 2022

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
November 11, 2022

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
November 10, 2022

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
November 10, 2022

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
November 09, 2022

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.